Epicelya Therapeutics AG

Epicelya Therapeutics AG is a Swiss biotechnology company specializing in the development of precision medicine through advanced mRNA technology platforms. The company focuses on addressing undruggable targets in oncology and age-related diseases. Its primary technological approaches include a precision epigenetic editing platform and a targeted cell elimination platform, both designed to provide high specificity with minimized off-target effects. These platforms utilize novel nuclease technologies and delivery systems optimized for systemic distribution, aiming to offer therapeutic solutions where traditional medicines have failed.

Headquartered in Allschwil, Switzerland, the company was established in late 2023 by a team of experienced biotech leaders and scientists, including CEO Dr. Jürg Stebler and CSO Dr. Sara Laudato. Epicelya is currently in the pre-clinical stage, focusing on the research and development of mRNA-based treatment strategies. By collaborating with academic institutions and industry leaders, the company works to translate innovative biological discoveries into scalable clinical solutions intended to treat severe diseases and significantly improve patient outcomes.